Preventing Delirium in Hospitalized Patients: No Magic Bullets
- PMID: 40558607
- DOI: 10.1097/CCM.0000000000006755
Preventing Delirium in Hospitalized Patients: No Magic Bullets
Keywords: delirium; orexin receptor antagonists; research methods.
Conflict of interest statement
Dr. Spence’s institution received funding from AOP Pharma; she received funding from VarmX and Trimedic; and she received support for article research from the Heart and Stroke Foundation of Canada New Investigator Award. Dr. Belley-Côté’s institution received funding from Abbott Laboratories and Trimedic Therapeutics; she received funding from Bayer, BMS-Pfizer, and Roche Diagnostics; and she is supported by the Clive Kearon career award (McMaster University, Department of Medicine). Ms. Fournier has disclosed that she does not have any potential conflicts of interest.
References
-
- Toor B, Ray LB, Pozzobon A, et al.: Sleep, orexin and cognition. Front Neurol Neurosci 2021; 45:38–51
-
- Ángeles-Castellanos M, Ramírez-Gonzalez F, Ubaldo-Reyes L, et al.: Loss of melatonin daily rhythmicity is asociated with delirium development in hospitalized older adults. Sleep Sci 2016; 9:285–288
-
- de Oliveira HM, Gallo Ruelas M, Valeriano FV, et al.: Efficacy of ramelteon, suvorexant, and lemborexant for delirium prevention in hospitalized patients: A systematic review and meta-analysis. Crit Care Med 2025; 53:e1781–e1789
-
- Sharma R, Sahota P, Thakkar MM: Melatonin promotes sleep in mice by inhibiting orexin neurons in the perifornical lateral hypothalamus. J Pineal Res 2018; 65:e12498
-
- Lewis K, Balas MC, Stollings JL, et al.: A focused update to the clinical practice guidelines for the prevention and management of pain, anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2025; 53:e711–e727
LinkOut - more resources
Full Text Sources
